Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure

Wissam Mattar, Beth Juliar, Irmina Gradus-Pizlo, Paul Y. Kwo

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Amiodarone is associated with varying degrees of hepatotoxicity. Aims: to study the association between the presence of the metabolic syndrome or right-sided heart failure and the prevalence of amiodarone induced liver disease. Methods: Retrospective chart review of patients who received amiodarone for ≥60 days at a university affiliated community hospital. We collected information about clinical progression and liver chemistries on 409 included patients. Subgroup analysis was based on the presence or absence of right-sided heart failure and the metabolic syndrome. Results: The 409 patients (58% male, 55% Caucasian) had a mean age of 62 years, mean follow up of 37.6 months and mean cumulative amiodarone dose of 295±404 grams. No subjects developed clinical hepatitis, cirrhosis or death related to amiodarone. Eight patients developed amiodarone hepatotoxicity, 5 required discontinuation and 3 required dose reduction of the medication with resolution of the transaminitis in all. No differences in liver chemistries at follow up between patients with or without the metabolic syndrome and with or without right cardiac dysfunction were noted. Conclusion: Administration of amiodarone was associated with a low incidence of hepatotoxicity without relationship to cumulative dose. The presence of the metabolic syndrome or right-sided heart failure does not increase the incidence of amiodarone hepatotoxicity.

Original languageEnglish
Pages (from-to)419-423
Number of pages5
JournalJournal of Gastrointestinal and Liver Diseases
Volume18
Issue number4
StatePublished - Dec 2009

Fingerprint

Amiodarone
Heart Failure
Liver
Incidence
Community Hospital
Hepatitis
Liver Diseases
Fibrosis

Keywords

  • Amiodarone
  • Congestive heart failure
  • Drug-induced hepatitis
  • Liver
  • Metabolic syndrome

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. / Mattar, Wissam; Juliar, Beth; Gradus-Pizlo, Irmina; Kwo, Paul Y.

In: Journal of Gastrointestinal and Liver Diseases, Vol. 18, No. 4, 12.2009, p. 419-423.

Research output: Contribution to journalArticle

Mattar, Wissam ; Juliar, Beth ; Gradus-Pizlo, Irmina ; Kwo, Paul Y. / Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. In: Journal of Gastrointestinal and Liver Diseases. 2009 ; Vol. 18, No. 4. pp. 419-423.
@article{2921bc18665146b995ee26de1430b1a7,
title = "Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure",
abstract = "Background: Amiodarone is associated with varying degrees of hepatotoxicity. Aims: to study the association between the presence of the metabolic syndrome or right-sided heart failure and the prevalence of amiodarone induced liver disease. Methods: Retrospective chart review of patients who received amiodarone for ≥60 days at a university affiliated community hospital. We collected information about clinical progression and liver chemistries on 409 included patients. Subgroup analysis was based on the presence or absence of right-sided heart failure and the metabolic syndrome. Results: The 409 patients (58{\%} male, 55{\%} Caucasian) had a mean age of 62 years, mean follow up of 37.6 months and mean cumulative amiodarone dose of 295±404 grams. No subjects developed clinical hepatitis, cirrhosis or death related to amiodarone. Eight patients developed amiodarone hepatotoxicity, 5 required discontinuation and 3 required dose reduction of the medication with resolution of the transaminitis in all. No differences in liver chemistries at follow up between patients with or without the metabolic syndrome and with or without right cardiac dysfunction were noted. Conclusion: Administration of amiodarone was associated with a low incidence of hepatotoxicity without relationship to cumulative dose. The presence of the metabolic syndrome or right-sided heart failure does not increase the incidence of amiodarone hepatotoxicity.",
keywords = "Amiodarone, Congestive heart failure, Drug-induced hepatitis, Liver, Metabolic syndrome",
author = "Wissam Mattar and Beth Juliar and Irmina Gradus-Pizlo and Kwo, {Paul Y.}",
year = "2009",
month = "12",
language = "English",
volume = "18",
pages = "419--423",
journal = "Journal of Gastrointestinal and Liver Diseases",
issn = "1841-8724",
publisher = "Romanian Society of Gastroenterology",
number = "4",

}

TY - JOUR

T1 - Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure

AU - Mattar, Wissam

AU - Juliar, Beth

AU - Gradus-Pizlo, Irmina

AU - Kwo, Paul Y.

PY - 2009/12

Y1 - 2009/12

N2 - Background: Amiodarone is associated with varying degrees of hepatotoxicity. Aims: to study the association between the presence of the metabolic syndrome or right-sided heart failure and the prevalence of amiodarone induced liver disease. Methods: Retrospective chart review of patients who received amiodarone for ≥60 days at a university affiliated community hospital. We collected information about clinical progression and liver chemistries on 409 included patients. Subgroup analysis was based on the presence or absence of right-sided heart failure and the metabolic syndrome. Results: The 409 patients (58% male, 55% Caucasian) had a mean age of 62 years, mean follow up of 37.6 months and mean cumulative amiodarone dose of 295±404 grams. No subjects developed clinical hepatitis, cirrhosis or death related to amiodarone. Eight patients developed amiodarone hepatotoxicity, 5 required discontinuation and 3 required dose reduction of the medication with resolution of the transaminitis in all. No differences in liver chemistries at follow up between patients with or without the metabolic syndrome and with or without right cardiac dysfunction were noted. Conclusion: Administration of amiodarone was associated with a low incidence of hepatotoxicity without relationship to cumulative dose. The presence of the metabolic syndrome or right-sided heart failure does not increase the incidence of amiodarone hepatotoxicity.

AB - Background: Amiodarone is associated with varying degrees of hepatotoxicity. Aims: to study the association between the presence of the metabolic syndrome or right-sided heart failure and the prevalence of amiodarone induced liver disease. Methods: Retrospective chart review of patients who received amiodarone for ≥60 days at a university affiliated community hospital. We collected information about clinical progression and liver chemistries on 409 included patients. Subgroup analysis was based on the presence or absence of right-sided heart failure and the metabolic syndrome. Results: The 409 patients (58% male, 55% Caucasian) had a mean age of 62 years, mean follow up of 37.6 months and mean cumulative amiodarone dose of 295±404 grams. No subjects developed clinical hepatitis, cirrhosis or death related to amiodarone. Eight patients developed amiodarone hepatotoxicity, 5 required discontinuation and 3 required dose reduction of the medication with resolution of the transaminitis in all. No differences in liver chemistries at follow up between patients with or without the metabolic syndrome and with or without right cardiac dysfunction were noted. Conclusion: Administration of amiodarone was associated with a low incidence of hepatotoxicity without relationship to cumulative dose. The presence of the metabolic syndrome or right-sided heart failure does not increase the incidence of amiodarone hepatotoxicity.

KW - Amiodarone

KW - Congestive heart failure

KW - Drug-induced hepatitis

KW - Liver

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=74949105745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949105745&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 419

EP - 423

JO - Journal of Gastrointestinal and Liver Diseases

JF - Journal of Gastrointestinal and Liver Diseases

SN - 1841-8724

IS - 4

ER -